Sandbox john2: Difference between revisions

Jump to navigation Jump to search
Line 1: Line 1:
==In Progress==
==In Progress==
The best approach to prevent [[measles]] is by active [[immunization]].<ref name="MossGriffin2012">{{cite journal|last1=Moss|first1=William J|last2=Griffin|first2=Diane E|title=Measles|journal=The Lancet|volume=379|issue=9811|year=2012|pages=153–164|issn=01406736|doi=10.1016/S0140-6736(10)62352-5}}</ref> Ever since the introduction of the [[vaccine]] in the developed world, there has been a marked reduction in the [[incidence]] of [[measles]], however, there are still some reported cases of the disease in low-incidence areas, usually imported from other countries by travelers. Because of this potential re-introduction of the virus, it is important to maintain a high level of immunity among the population in order to prevent outbreaks. The measles vaccine is recommended in all infants, as well as in all adolescents and adults of high-risk. When evaluating the need to administer the vaccine, important factors should be attended:
*Age
*Date of administration of first dose, in case of such existence.
*Local measles virus epidemiology, including:
:*Risk of exposure
:*Kind of measles vaccine previously administrated
:*Existence of contraindications for vaccination
:*History of prior measles infection
:*Near-future travel plans


About the type of vaccine, the measles vaccine is an attenuated form, in which is present an attenuated strain of the virus, which distinguishes it from the wild-type strain and at the same time decreases its tropism for lymphocytes.<ref name="MossGriffin2012">{{cite journal|last1=Moss|first1=William J|last2=Griffin|first2=Diane E|title=Measles|journal=The Lancet|volume=379|issue=9811|year=2012|pages=153–164|issn=01406736|doi=10.1016/S0140-6736(10)62352-5}}</ref><ref name="pmid11134304">{{cite journal| author=Parks CL, Lerch RA, Walpita P, Wang HP, Sidhu MS, Udem SA| title=Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage. | journal=J Virol | year= 2001 | volume= 75 | issue= 2 | pages= 910-20 | pmid=11134304 | doi=10.1128/JVI.75.2.910-920.2001 | pmc=PMC113987 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11134304  }} </ref><ref name="pmid17624839">{{cite journal| author=Condack C, Grivel JC, Devaux P, Margolis L, Cattaneo R| title=Measles virus vaccine attenuation: suboptimal infection of lymphatic tissue and tropism alteration. | journal=J Infect Dis | year= 2007 | volume= 196 | issue= 4 | pages= 541-9 | pmid=17624839 | doi=10.1086/519689 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17624839  }} </ref>
Currently in the US, the available vaccine is the ''Enders-Edmonston strain''. This is a live attenuated vaccine, licensed in 1968. It has two formulations:<ref name="MossGriffin2012">{{cite journal|last1=Moss|first1=William J|last2=Griffin|first2=Diane E|title=Measles|journal=The Lancet|volume=379|issue=9811|year=2012|pages=153–164|issn=01406736|doi=10.1016/S0140-6736(10)62352-5}}</ref><ref name="LeuridanHens2010">{{cite journal|last1=Leuridan|first1=E.|last2=Hens|first2=N.|last3=Hutse|first3=V.|last4=Ieven|first4=M.|last5=Aerts|first5=M.|last6=Van Damme|first6=P.|title=Early waning of maternal measles antibodies in era of measles elimination: longitudinal study|journal=BMJ|volume=340|issue=may18 2|year=2010|pages=c1626–c1626|issn=0959-8138|doi=10.1136/bmj.c1626}}</ref>
*MMR or Measles-Mumps-Rubella vaccine
*Quadrivalent MMRV vaccine with measles, mumps, rubella, and varicella.
According to the CDC, every child should get 2 doses of the MMR vaccine:
*The first dose should be between the 12th and the 15th month of life
*The second dose can be given at any age, as long as there are at least 28 days after the administration of the first dose. However, common practice is to administer the second dose between the 4th and the 6th year of life.
It is important to notice that for any international travel, children between 6 and 11 months of age should have at least one dose of the MMR vaccine. If the child has more than one year of age, then he/she should have the two doses of the MMR vaccine, interspaced at least by 28 days. The two doses of the vaccine are required in order to develop the required immunity to avoid transmission.





Revision as of 19:35, 24 June 2014

In Progress

Adults DO NOT need the measles, mumps, rubella vaccine (MMR) if:

  • Blood tests show immunity to measles, mumps, and rubella.
  • You are a man born before 1957.
  • You are a woman born before 1957 who is sure she is not having more children, has already had rubella vaccine, or has had a positive rubella test.
  • You already had two doses of MMR or one dose of MMR plus a second dose of measles vaccine.
  • You already had one dose of MMR and are not at high risk of measles exposure.

Adults SHOULD get the measles vaccine if you are not among the categories listed above, and:

  • You are a college student, trade school student, or other student beyond high school.
  • You work in a hospital or other medical facility*.
  • You travel internationally, or are a passenger on a cruise ship.
  • You are a woman of childbearing age.

Random notes


CS Ultrasound: Echocardiography is an important imaging modality in the evaluation of the patient with cardiogenic shock. In cardiogenic shock complicating acute-MI, findings such as poor wall motion may be identified. Mechanical complications such as papillary muscle rupture, pseudoaneurysm, and a ventricular septal defect may also be visualized. Valvular heart disease such as aortic stenosis, aortic insufficiency and mitral stenosis can also be assessed. Dynamic outflow obstruction such as HOCM can also be indentified and quantified. The magnitude of left ventricular dysfunction in patients with cardiomyopathy can be evaluated. It allows the clinician to distinguish cardiogenic shock from septic shock and neurogenic shock. In septic shock, a hypercontractile ventricle may be present.


  • Differential diagnosis - "Cardiogenic shock may be difficult, at least initially, to distinguish from hypovolemic shock. Both forms of shock are associated with decreased cardiac output and compensatory upregulation of the sympathetic response. Both entities also respond initially to fluid resuscitation. The syndrome of cardiogenic shock is defined as the inability of the heart to deliver sufficient blood flow to meet metabolic demands. The etiology of cardiogenic shock may be intrinsic or extrinsic. In Case 1 , the development of class IV shock may be due to hemorrhage, such as an aortic injury, or may be cardiogenic, such as a myocardial contusion from blunt injury to the chest. Echocardiography would evaluate the possibility of intrinsic or extrinsic myocardial dysfunction. Intrinsic causes of cardiogenic shock include myocardial infarction, valvular disease, contusion from thoracic trauma, and arrhythmias. For patients with myocardial infarction, cardiogenic shock is associated with loss of greater than 40% of left ventricular myocardium. The normal physiologic compensation for cardiogenic shock actually results in progressively greater myocardial energy demand that, without intervention, results in the death of the patient . A decrease in blood pressure activates an adrenergic response that leads to increased sympathetic tone, stimulates renin-angiotensinaldosterone feedback, and potentiates antidiuretic hormone secretion. These mechanisms serve to increase vasomotor tone and retain salt and water. The resultant increase in systemic vascular resistance and in left ventricular end-diastolic pressure leads to increased myocardial oxygen demand in the face of decreased oxygen delivery. This, in turn, results in worsening left ventricular function, a perceived reduction in circulating blood volume, and repetition of the cycle."

Cardiogenic shock and Inflammatory Mediators

The Pathophysiologic "Spiral" of Cardiogenic shock

Among patients with acute MI, there is often a downward spiral of hypoperfusion leading to further ischemia which leads to a further reduction in cardiac output and further hypoperfusion. The lactic acidosis that develops as a result of poor systemic perfusion can further reduce cardiac contractility. Reduced cardiac output leads to activation of the sympathetic nervous system, and the ensuing tachycardia that develops further exacerbates the myocardial ischemia. The increased left ventricular end diastolic pressures is associated with a rise in wall stress which results in further myocardial ischemia. Hypotension reduces epicardial perfusion pressure which in turn further increases myocardial ischemia.

Patients with cardiogenic shock in the setting of STEMI more often have multivessel disease, and myocardial ischemia may be present in multiple territories. It is for this reason that multivessel angioplasty may be of benefit in the patient with cardiogenic shock.

The multifactorial nature of cardiogenic shock can also be operative in the patient with critical aortic stenosis who has "spiraled": There is impairment of left ventricular outflow, with a drop in cardiac output there is greater subendocardial ischemia and poorer flow in the coronary arteries, this leads to further left ventricular systolic dysfunction, given the subendocardial ischemia, the left ventricle develops diastolic dysfunction and becomes harder to fill. Inadvertent administration of vasodilators and venodilators may further reduce cardiac output and accelerate or trigger such a spiral.

Pathophysiologic Mechanisms to Compensate for Cardiogenic shock

Cardiac output is the product of stroke volume and heart rate. In order to compensate for a reduction in stroke volume, there is a rise in the heart rate in patients with cardiogenic shock. As a result of the reduction in cardiac output, peripheral tissues extract more oxygen from the limited blood that does flow to them, and this leaves the blood deoxygenated when it returns to the right heart resulting in a fall in the mixed venous oxygen saturation.

Pathophysiology of Multiorgan Failure

The poor perfusion of organs results in hypoxia and metabolic acidosis. Inadequate perfusion to meet the metabolic demands of the brain, kidneys and heart leads to multiorgan failure.


++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++


Differential Diagnosis


Classification of shock based on hemodynamic parameters. (CO, cardiac output; CVP; central venous pressure; PAD, pulmonary artery diastolic pressure; PAS, pulmonary artery systolic pressure; RVD, right ventricular diastolic pressure; RVS, right ventricular systolic pressure; SVO2, systemic venous oxygen saturation; SVR, systemic vascular resistance.)[1][2]
Type of Shock Etiology CO SVR PCWP CVP SVO2 RVS RVD PAS PAD
Cardiogenic Acute Ventricular Septal Defect ↓↓ N — ↑ ↑↑ ↑ — ↑↑ N — ↑ N — ↑ N — ↑
Acute Mitral Regurgitation ↓↓ ↑↑ ↑ — ↑↑ N — ↑
Myocardial Dysfunction ↓↓ ↑↑ ↑↑ N — ↑ N — ↑ N — ↑
Right Ventricular Infarction ↓↓ N — ↓ ↑↑ ↓ — ↑ ↓ — ↑ ↓ — ↑
Obstructive Pulmonary Embolism ↓↓ N — ↓ ↑↑ ↓ — ↑ ↓ — ↑ ↓ — ↑
Cardiac Tamponade ↓ — ↓↓ ↑↑ ↑↑ N — ↑ N — ↑ N — ↑
Distributive Septic Shock N — ↑↑ ↓ — ↓↓ N — ↓ N — ↓ ↑ — ↑↑ N — ↓ N — ↓
Anaphylactic Shock N — ↑↑ ↓ — ↓↓ N — ↓ N — ↓ ↑ — ↑↑ N — ↓ N — ↓
Hypovolemic Volume Depletion ↓↓ ↓↓ ↓↓ N — ↓ N — ↓

References

  1. Parrillo, Joseph E.; Ayres, Stephen M. (1984). Major issues in critical care medicine. Baltimore: William Wilkins. ISBN 0-683-06754-0.
  2. Judith S. Hochman, E. Magnus Ohman (2009). Cardiogenic Shock. Wiley-Blackwell. ISBN 9781405179263.